Mylan Continues to Pursue Damages and Injunction; Watson Launches Generic Version of Prometrium Print E-mail
By Staff and Wire Reports   
Friday, 02 March 2012 19:44
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 2, 2012.

Mylan Inc. (Nasdaq: MYL) commented on a ruling for partial summary judgment in its patent infringement lawsuit against Sunovion Pharmaceuticals Inc. in relation to Sunovion's Brovana® product. The U.S. District Court for the Southern District of New York granted Sunovion's motion regarding one of Sunovion's defenses and its request to limit damages.

Mylan is disappointed in the ruling and believes the Court erred in its decision. Mylan intends to appeal the decision. In addition, Mylan's two reexamined patents remain the subject of ongoing litigation and the company intends to continue to pursue damages and an injunction with respect to those patents.  Mylan also will continue to pursue its claims against Teva (NASDAQ:TEVA) in separate litigation.


Watson Pharmaceuticals (NYSE:WPI) confirmed that it has launched an authorized generic version of PROMETRIUM Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories (NYSE:ABT).

Under the terms of the supply agreement, Abbott manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.

Also Friday:

Abiomed, Inc. (NASDAQ: ABMD)
, a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President and Chief Financial Officer of Abiomed, will present at the Cowen 32nd Annual Healthcare Conference on Monday, March 5, 2012 at 1:30 p.m. ET.

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR)
, a specialty pharmaceutical company innovating abuse deterrent drugs, today announced independent laboratory tests demonstrated that NEXAFED, Acura's pseudoephedrine tablet product, disrupted the conversion of the pseudoephedrine in the product into methamphetamine.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
today announced that company management will participate at the 24th Annual ROTH Conference on March 13 at 4:30 pm PT in Dana Point, CA.

ArQule, Inc. (Nasdaq: ARQL)
today announced that the Company will present at the Cowen and Company 32nd Annual Healthcare Conference on March 7, 2012 at 10:00 a.m.

Baxter International Inc. (NYSE: BAX)
today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies (PI).

Cannabis Science, Inc. (OTCBB:CBIS.OB)
a pioneering U.S. biotech company developing pharmaceutical cannabis and hemp products, issues market data for the four Cannabis Science brand products for the newest over-the-counter line to be released.

Baxter International Inc. (NYSE:BAX) announced today that the European Commission (EC) has granted marketing authorization for VEPACEL in all European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that preliminary results from the ADACTA (ADalimumab ACTemrA) study showed that patients who received ACTEMRA® (tocilizumab) as monotherapy achieved a significantly greater reduction in disease activity (assessed by the mean change of DAS281) after 24 weeks than those given adalimumab monotherapy.

Given Imaging Ltd. (NASDAQ: GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that the Company will participate in multiple events in honor of National Colorectal Cancer Awareness Month.

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 7, 2012 at the Cowen and Co. Annual Health Care Conference in Boston.

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its third quarter of Fiscal Year 2012 ended January 31, 2012, prior to the market opening on Thursday March 8, 2012 and will hold a conference call to discuss its financial results at 11 a.m. Eastern Time.

As clinical trial sponsors increase their focus on reducing costs, accelerating studies and mitigating risk, contract research organizations (CROs) continue to look to Medidata Solutions (NASDAQ: MDSO) as a leading source of clinical development technology.

Osiris Therapeutics, Inc. (NASDAQ: OSIR)
today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2011, on Friday, March 9, 2012.

Senesco Technologies, Inc. (NYSE AMEX: SNT) announced today that it has entered into a securities purchase agreement to raise an additional $1.0 million in gross proceeds through the sale of 3,846,154 shares of its common stock.

Syneron Medical Ltd. (NASDAQ: ELOS)
, the leading global aesthetic device company, announced today that is has closed its previously announced acquisition of Ultrashape Ltd. ("Ultrashape"), a leading developer, manufacturer and marketer of innovative non-invasive technologies for fat cell destruction and body sculpting.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories’ Prometrium® Capsules.

TherapeuticsMD™, Inc. (OCTQB: TXMD)
, parent company of vitaMedMD™, LLC ("vitaMedMD"), a specialty pharmaceutical company, announced today the election of four additional members to its Board of Directors including Samuel A. Greco, Cooper Collins, Robert V. LaPenta, Jr. and Nicholas Segal.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus